Corporate & Securities

Securities

Life as a public company continues to grow in complexity and challenges. It is essential to retain counsel with the securities experience and industry knowledge to guide you quickly and efficiently through everything from capital-raising transactions and sensitive disclosure issues, to Securities and Exchange Commission compliance and reporting, and corporate governance and stockholder interactions.

Mintz Levin represents issuers, underwriters, and investors in the full range of sophisticated securities transactions, from private placements and venture capital investments to initial and follow-on public offerings of equity, debt, and other securities, including registered direct offerings, PIPEs and confidentially marketed public offerings, and reverse mergers and other “alternative” means of accessing capital. We draw from extensive transactional experience and deep industry knowledge when representing you in your financing transactions and interactions with the Securities and Exchange Commission. We also represent buyers and sellers of businesses in merger and acquisition transactions in which securities are used as transaction consideration.

We represent our public company clients with respect to ongoing Securities and Exchange Commission compliance obligations, including periodic reporting, stockholder interactions, equity compensation matters, officer and director reporting requirements, and managing disclosure considerations. We also counsel companies and their boards of directors and board committees on the corporate governance obligations and requirements of the Dodd-Frank Act, Sarbanes-Oxley, and state corporate law. We approach sensitive disclosure issues with a comprehensive understanding of the industries in which you operate and the issues that are most important to you and your stockholders.

Quick Facts


  • Recognized industry knowledge in life sciences, biotechnology, and energy and clean technology
  • Completed more than 65 public offerings since 2010, with an aggregate deal value of over $3.7 billion
  • Counsel to the world’s leading investment banks and many industry-focused niche and specialty firms
  • Specialize in IPO work for companies developing ground-breaking technologies:
    • First biotech: Biogen
    • First demand response: EnerNOC
    • First NYSE-listed SPAC: Navios Maritime
  • Access to firm’s Securities Litigation attorneys

Areas of Focus

  • Board and committee advice
    • Counsel concerning the requirements and restrictions imposed on boards and board committees by securities laws
  • Capital-raising transactions
    • IPOs, underwritten follow-ons and registered directs, PIPEs, confidentially marketed public offerings, SPACs, and equity and debt offerings, including Rule 144A convertible notes
  • Corporate governance strategies
    • Sarbanes-Oxley and Dodd-Frank compliance and related governance issues
  • Executive and equity compensation planning and implementation
    • Structuring and implementing employee benefit plans and equity compensation packages under SEC’s “short-swing profit” reporting and liability rules, Section 13 and Section 16 reporting, and 10b5-1 plans
  • SEC and stock exchange reporting
    • Periodic and current reports, disclosure controls and procedures, and stock exchange listing standards
  • Securities education and training
    • Ensuring clients stay current with regulations and best practices
  • Shareholder communications and reporting
    • Assisting with the annual meeting process, Regulation FD compliance, and institutional shareholder issues
  • Mergers and acquisitions involving public company securities
    • Deal structuring, SEC disclosure and filings, corporate takeover defenses, and strategy
  • Policies and procedures
    • Implementing codes of conduct, insider trading policies and programs, and other means of managing life as a public company
Sort by: Name  Title  Office

Priya K. Agrawal

Priya K. Agrawal

Associate

212.692.6708

Avisheh Avini

Avisheh Avini

Of Counsel

212.692.6200

617.348.1784

617.348.1840

617.348.1742

John P. Condon

John P. Condon

Associate

617.348.4453

617.348.3008

617.348.1741

617.348.1640

617.348.4474

Julia F. Gaffin

Julia F. Gaffin

Associate

212.692.6744

Steve Ganis

Steve Ganis

Of Counsel

617.348.1672

617.348.4443

Merav Gershtenman

Merav Gershtenman

Associate

212.692.6806

Ilan Goldbard

Ilan Goldbard

Associate

212.692.6817

617.348.1706

617.348.1715

617.348.3093

212.692.6768

617.348.1674

617.348.4402

Jessica D. Mendoza

Jessica D. Mendoza

Associate

415.432.6085

Tavis J. Morello

Tavis J. Morello

Associate

617.348.4464

Mark Nemes

Mark Nemes

Associate

212.692.6718

212.692.6774

617.348.1841

Linda Rockett

Linda Rockett

Member

617.348.4888

John T. Rudy

John T. Rudy

Associate

617.348.3050

858.314.1873

617.348.1798

212.692.6732

Jonathan Urbon

Jonathan Urbon

Associate

617.348.1844

Adam M. Veness

Adam M. Veness

Associate

617.348.4432

617.348.1869

Garrett M. Winslow

Garrett M. Winslow

Associate

617.348.3028

Representative Experience

  • Served as underwriters’ counsel to Leerink Swann in the $23.7 million underwritten public offering in January 2012 by Chelsea Therapeutics International Ltd. (NASDAQ: CHTP).
  • Represented ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) in its $258 million public offering in December 2011. JPMorgan, Cowen and Company, and Jefferies served as underwriters.
  • Represented GI Dynamics, Inc. (ASX: GID) in the filing of its Australian IPO and contemporaneous US private placement, which raised a combined $85 million in September 2011.
  • Served as placement agent counsel to Leerink Swann in the $55 million private placement in September 2011 by Puma Biotechnology.
  • Represented BofA Merrill Lynch and Leerink Swann as underwriters’ counsel in a $65 million shelf offering for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) in June 2011.
  • Represented ImmunoGen Inc., (NASDAQ: IMGN) in its $93.6 million follow-on underwritten public offering in May 2011. Jefferies & Company Inc. acted as the sole book-running manager for the offering and Oppenheimer & Co. Inc., RBC Capital Markets LLC, William Blair & Company LLC, Canaccord Genuity Inc., and Morgan Joseph TriArtisan LLC acted as co-managers for the offering.
  • Represented Rosetta Genomics, Inc. (NASDAQ: ROSG) in its concurrent PIPE / registered direct offering in February 2011. Rodman & Renshaw acted as the exclusive placement agent for both offerings.
  • Represented Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in its $400 million underwritten public offering in September 2010. BofA Merrill Lynch acted as the sole underwriter in the offering.
  • Represented Navios Maritime Acquisition Corporation (NYSE: NNA.U) in its $90 million public offering in August 2010. Among the many offerings that we have done for Navios and its affiliates, in 2008, we completed Navios’s IPO of approximately $253 million, which made Navios the first SPAC initially listed on the NYSE.

Past